Business Context and Reporting Period
ImmuCell Corporation (ICCC), a Delaware corporation headquartered in Portland, Maine, filed this Form 8-K on April 8, 2026. The report addresses preliminary, unaudited financial results for the first quarter (Q1) ended March 31, 2026.
Key Financial Metrics
- Product Sales Growth: Reported a 28.4% increase in product sales for Q1 2026 compared to Q1 2025.
- Revenue, Profit, and Cash Flow: The filing text does not provide specific dollar values for total revenue, net income, operating cash flow, or margins.
- Debt and Liquidity: The filing text does not provide specific data regarding debt levels or liquidity positions.
Material Changes
The primary material change disclosed is the significant year-over-year growth in product sales volume or value, rising 28.4% in the current quarter relative to the prior year period.
Guidance, Outlook, and Risks
The filing references a press release (Exhibit 99.1) containing the full announcement but does not include specific forward-looking guidance, management commentary, risk factors, or contingencies within the body of this 8-K text. The financial data presented is preliminary and unaudited.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for absolute revenue figures and margin details not included in this summary.
- Verify the definition of "product sales" used in the 28.4% growth calculation (e.g., gross sales vs. net revenue).
- Confirm the impact of this sales increase on the company's cash burn rate and liquidity runway.
- Check for any accompanying guidance on full-year 2026 performance in the referenced press release.